ProCE Banner Series

Driving Improved Outcomes in Resectable Melanoma: Pathways for Optimized Adjuvant Immunotherapy Strategies

Gain expert insight on optimizing the use of adjuvant immunotherapy for patients with resectable melanoma in these interactive, expert led  CME/CNE/CPE-certified 1-hr workshops.

To Register:  Please click the green “Learn More” button below. On the next page, select Register for Virtual Event. Once registered, you will receive a confirmation email. Follow-up emails with event details will be sent as the event nears.

  | ACPE
  | AMA
  | ANCC
Who Should Attend

This educational program is intended for medical oncologists, dermatologists, surgeons, nurses, pharmacists, physicians associates, and other healthcare professionals caring for patients with melanoma

All Events

Driving Improved Outcomes in Resectable Melanoma: Pathways for Optimized Adjuvant Immunotherapy Strategies [Open Registration]

Past Events




11:30 AM - 12:30 PM Central Time (CT)


CCO Simulcast | Host Group TX, San Antonio, Texas




11:30 AM - 12:30 PM Eastern Time (ET)


CCO Simulcast | Host Group MD, Baltimore, Maryland


ProCE Banner Faculty
Michael A. Davies, MD, PhD

Professor and Chair, Department of Melanoma Medical Oncology
Professor, Translational Molecular Pathology and Genomic Medicine
Anne and John Mendelsohn Chair in Cancer Research
University of Texas, MD Anderson Cancer Center
Houston, Texas

ProCE Banner Faculty
Evan J. Lipson, MD

Associate Professor of Oncology
Melanoma and Cancer Immunology Programs
Bloomberg-Kimmel Institute for Cancer Immunotherapy
Johns Hopkins University School of Medicine
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

ProCE Banner Faculty
Tara C. Mitchell, MD

Associate Professor of Medicine
Section Chief, Melanoma/Sarcoma, Division of Hematology/Oncology
Director of Clinical Research
Tara Miller Melanoma Center
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania

ProCE Banner Faculty
April Salama, MD

Associate Professor of Medicine
Division of Medical Oncology
Director, Melanoma Program
Duke Cancer Institute
Durham, North Carolina


  • Welcome, Introduction, and Baseline Assessment
  • Introduction and Landscape Overview of Early-Stage High-Risk Melanoma
  • Advancing Therapeutic Options with Adjuvant Immunotherapy for the Treatment of Stage IIB/C Melanoma
  • Maximizing Therapeutic Success: Harnessing Effective Strategies for Adverse Event Recognition and Management
  • Collaborative Personalization: Enhancing Patient Outcomes Through Interdisciplinary Teamwork and Patient-Centric Care
  • Question and Answer Session

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.


Goal Statement
The goal of this program is to improve the knowledge, competence, and performance of learners in effort to optimize treatment for patients with Melanoma 

Target Audience
This educational program is intended for medical oncologists, dermatologists, surgeons, nurses, pharmacists, physicians associates, and other healthcare professionals caring for patients with melanoma 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Synthesize and apply the clinical data on immunotherapy use in early-stage melanoma, particularly adjuvant therapy for stage IIB/C disease, to improve understanding and effectively implement these treatment strategies.
  • Devise concise, patient-specific treatment plans integrating adjuvant immunotherapy for stage IIB/C melanoma, factoring in recurrence prevention, outcome improvement, and management of immune-related adverse events.
  • Foster effective collaboration within the multidisciplinary team, leveraging shared knowledge and expertise to integrate immunotherapy into tailored multimodal treatment plans early in the disease process for eligible melanoma patients, enhancing patient care and clinical outcomes.
  • Employ shared decision-making strategies to empower patients, thereby building trust within the patient-clinician relationship, and subsequently, implement personalized treatment plans that align with patients' unique goals and preferences.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-23-252-L01-P 

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim commensurate with the extent of their participation.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


Provided by Clinical Care Options, LLC, in partnership with AIM at Melanoma Foundation.

Supported by an educational grant from Bristol Myers Squibb.